
North Dakota Medicaid Pharmacy Program Quarterly News

Published Quarterly by Health Information Designs, LLC

Welcome to the “North Dakota Medicaid Pharmacy Program Quarterly News,” a pharmacy newsletter presented by the North Dakota Department of Human Services and published by Health Information Designs, LLC. This newsletter is published as part of a continuing effort to keep the Medicaid provider community informed of important changes in the North Dakota Medicaid Pharmacy Program.

The North Dakota Department of Human Services has contracted with Health Information Designs, LLC (HID) to review and process prior authorizations (PAs) for medications. For a current list of medications requiring a PA, as well as the necessary forms and criteria, visit www.hidesigns.com/ndmedicaid, or call HID at (866) 773-0695 to have this information faxed. An important feature on this website is the NDC Drug Lookup. This allows you to determine if a specific NDC is covered (effective date), reimbursement amount, MAC pricing, copay information, and any limitations (prior authorization or quantity limits).

This newsletter provides information regarding significant new dosage forms introduced in 2015. Also included is the top 25 drug list of second quarter 2015 by claims cost and claims count.

The North Dakota Medicaid Pharmacy Program team appreciates your comments and suggestions regarding this newsletter. To suggest topics for inclusion, or to make comments, please contact Health Information Designs, LLC at (334) 502-3262, call toll free at 1-800-225-6998, or e-mail us at info@hidinc.com.



Helpful Numbers

PA Help Desk	866-773-0695
To fax PAs	855-207-0250
To report adverse reactions	800-FDA-1088

Inside this issue:	Page
Welcome	1
Helpful Numbers	1
Significant New Dosage Forms 2015	2
Top 25 by Cost and Claims Count	3
Health Information Designs, LLC	4

Visit HID's North Dakota Department of Human Services Prior Authorization Webpage, www.hidesigns.com/ndmedicaid.

Significant New Dosage Forms 2015

Brand/Generic Name	Description
Aptensio XR (methylphenidate)	Extended-release capsule formulation for ADHD.
Belbuca (buprenorphine)	Buccal film formulation for chronic pain management.
Duopa (carbidopa/levodopa)	Enteral suspension formulation for patients with advanced Parkinson's disease.
Durlazza (aspirin)	Extended-release formulation for secondary prevention of CV events.
Dutrebis (lamivudine/raltegravir)	Combination product for treatment of HIV-1 infection.
Dyanavel XR (amphetamine)	Extended-release oral suspension for ADHD.
Enstilar (calcipotriene/betamethasone)	Topical foam formulation for plaque psoriasis.
Envarsus XR (tacrolimus)	Extended-release tablets to prevent organ rejection.
Evotaz (atazanavir/cobicistat)	A protease inhibitor and pharmacokinetic booster for HIV-1 infection
Glyxambi (empagliflozin/linagliptin)	Combination SGLT2 inhibitor and DPP-4 inhibitor for type 2 diabetes.
Invega Trinza (paliperidone)	Longer-acting injectable atypical antipsychotic.
Jadenu (deferasirox)	Oral tablet formulation iron chelator for chronic iron overload.
Morphabond (morphine)	Extended-release tablet formulation for severe chronic pain.
Narcan (naloxone)	Nasal spray formulation for emergency treatment of opioid overdose.
Onivyde (irinotecan)	Liposome formulation for advanced pancreatic cancer.
Otiprio (ciprofloxacin)	Otic suspension formulation for intratympanic administration only.
Prestalia (perindopril/amlodipine)	Combination ACEI and calcium channel blocker for hypertension.
Prezcobix (darunavir/cobicistat)	Protease inhibitor and pharmacokinetic booster for HIV-1 infection.
Quillichew ER (methylphenidate)	Extended-release chewable tablets for ADHD.
Rytary (carbidopa/levodopa)	Extended-release capsule formulation for Parkinson's disease and other forms of parkinsonism.
Ryzodeg (insulin degludec/insulin aspart)	A 70/30 mix insulin analog for diabetes.
Seebri Neohaler (glycopyrrolate)	Anticholinergic oral inhaler for COPD.
Spritam (levetiracetam)	Orally disintegrating tablet formulation for seizure control.
Stiolto Respimat (tiotropium/olodaterol)	Combination long-acting anticholinergic/beta-agonist oral inhaler for COPD.
Synjardy (empagliflozin/metformin)	Combination SGLT2 inhibitor and metformin for type 2 diabetes.
Technivie (ombitasvir/paritaprevir/ritonavir)	Oral combination formulation for chronic hepatitis C.
Tolak (fluorouracil)	A 4% topical cream formulation for actinic keratosis.
Toujeo (insulin glargine)	U-300 strength long-acting insulin for diabetes.
Triferic (ferric pyrophosphate citrate)	Iron replacement (via hemodialysate) in patients with hemodialysis-dependent chronic kidney disease.
Tuzistra XR (codeine/chlorpheniramine polistirex)	An opioid/antihistamine combination for relief of cough.
Ultravate (halobetasol)	Lotion formulation for plaque psoriasis.
Utibron Neohaler (indacaterol/glycopyrrolate)	Combination LABA and anticholinergic oral inhaler for COPD.
Vistogard (uridine triacetate)	An oral formulation for emergency treatment of fluorouracil or capecitabine overdose or severe toxicity.
Vivlodex (meloxicam)	Low-dose formulation for osteoarthritis pain.

Top 25 Drugs for 2nd Quarter 2015

Drug Name	Total Claims	Paid Amount	Drug Name	Total Claims	Paid Amount
HYDROCODONE-APAP	3,596	73,507.71	ABILIFY	883	725,389.74
AMOXICILLIN	3,318	34,763.25	METHYLPHENIDATE ER	1,981	328,262.35
OMEPRAZOLE	2,790	30,138.62	VYVANSE	1,437	263,283.32
PROVENTIL HFA	2,468	177,093.64	LYRICA	605	199,663.83
GABAPENTIN	2,182	50,342.83	LANTUS SOLOSTAR	448	188,019.39
SERTRALINE HCL	2,060	19,642.94	PROVENTIL HFA	2,468	177,093.64
AZITHROMYCIN	2,027	36,707.54	ENBREL	49	176,949.40
METHYLPHENIDATE ER	1,981	328,262.35	BUDESONIDE	584	174,590.76
MONTELUKAST	1,980	40,769.27	ADVAIR DISKUS	556	173,070.01
LEVOTHYROXINE	1,909	32,484.57	NOVOLOG FLEXPEN	358	173,044.21
FLUOXETINE HCL	1,857	12,285.43	STRATTERA	599	169,223.71
TRAZODONE HCL	1,783	12,715.59	LEVEMIR FLEXTOUCH	310	157,053.89
LISINAPRIL	1,768	12,741.40	FREESTYLE LITE STRIPS	961	144,559.10
OXYCODONE-APAP	1,464	47,501.38	DEXTROAMPH-AMPHET	1,319	140,105.35
CLONIDINE HCL	1,440	11,311.25	COPAXONE	22	137,163.82
VYVANSE	1,437	263,283.32	GUANFACINE HCL ER	815	127,354.37
AMOX TR-POT CLAV	1,430	36,552.88	LATUDA	156	125,690.05
TRAMADOL HCL	1,368	11,332.80	HELIXATE FS	5	113,467.84
BUPROPION XL	1,357	30,137.80	SEROQUEL XR	233	112,404.21
METFORMIN HCL	1,325	10,789.33	INVEGA SUSTENNA	72	111,763.94
RISPERIDONE	1,324	16,619.59	ARIPIRAZOLE	273	111,040.07
DEXTROAMPHE-AMPHET	1,319	140,105.35	SPIRIVA	276	87,674.41
ATORVASTATIN	1,315	13,646.96	INVEGA	93	84,948.78
CLONAZEPAM	1,297	9,504.92	VIMPAT	150	83,613.90
QUETIAPINE FUMARATE	1,281	20,680.68	AUVI-Q	181	81,171.13
Top 25 by Claims Count	46,076	1,472,921.40	Top 25 by Claims Cost	14,834	4,366,601.22



health information
designs

Health Information Designs, LLC is the most experienced and qualified provider of drug utilization review and pharmacy support services in the country. We specialize in helping our clients promote clinically appropriate and cost-effective prescribing, dispensing, and utilization of prescription drugs.



391 Industry Drive
Auburn, AL 36832
Tel: 800-748-0130
Fax: 800-748-0116

PRST STD
U.S.
Postage